Physician profile
Asgar A Boxwalla
NPI 1740248541
$2,919.01
in general payments reported to CMS, 2019-2025
23 companies · $640 in 2025
The $640 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $118 · 2021: $314 · 2022: $358 · 2023: $358 · 2024: $625 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,622 · Education: $1.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,621.74 |
| Education | $1.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $571.50 | 2021-2025 | Fetroja |
| Insmed, INC. | $457.61 | 2019-2025 | Arikayce, Brinsupri |
| Abbvie INC. | $330.89 | 2021-2025 | Avycaz, Teflaro |
| Gilead Sciences, INC. | $289.77 | 2020-2025 | Biktarvy |
| Aimmune Therapeutics, INC. | $178.50 | 2023-2025 | Vowst, Zenpep |
| Melinta Therapeutics, LLC | $152.40 | 2019-2025 | Rezzayo, Kimyrsa |
| Allergan, INC. | $137.92 | 2019-2020 | |
| Philips North America LLC | $132.30 | 2024 | (9520) Igt Devices Undivided |
| Tetraphase Pharmaceuticals, INC. | $122.34 | 2019-2025 | |
| La Jolla Pharmaceutical Company | $122.18 | 2022-2025 | Xerava, Zevtera |
| Paratek Pharmaceuticals, INC. | $76.24 | 2024-2025 | Nuzyra |
| Amgen INC. | $61.28 | 2020-2024 | Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $50.09 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $43.28 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.82 | 2019-2023 | Xifaxan |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.69 | 2019-2023 | Dificid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.76 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $19.50 | 2025 | Rexulti |
| Nestle Healthcare Nutrition INC. | $19.12 | 2023 | |
| Phathom Pharmaceuticals, INC. | $17.10 | 2024 | Voquezna |
| Novo Nordisk INC | $15.17 | 2023 | Rybelsus, Ozempic |
| Pfizer INC. | $13.63 | 2019 | |
| Advanced Respiratory, INC | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asgar Boxwalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.